

CURRICULUM VITAE DE-COLLE CHIARA

DATI PERSONALI

Nome: Chiara De-Colle
Data di nascita: 16.12.1985
Luogo di nascita: Ivrea

ISTRUZIONE ED ESPERIENZE PROFESSIONALI

10.06.204-oggi	Medico specialista, IRCCS Ospedale Sacro Cuore Don Calabria di Negrar, Negrar di Valpolicella, Verona, Italia
09.01.2017–31.05.2024	Medico specialista, Dipartimento di Radioterapia, Università di Tübingen, Germania
20.05.2020	Certificato ministeriale della Regione Baden-Württemberg per l'insegnamento della medicina
11.09.2018	Promozione, Facoltà di Medicina, Università di Tübingen, Germania. Titolo della tesi: SDF-1/CXCR4 as prognostic markers for postoperative radiochemotherapy in head and neck cancer. Relatore: Prof. Dr. med. D. Zips
01.09.2016–31.12.2016	Medico ricercatore, Università di Tübingen, Germania
28.06.2011–05.07.2016	Scuola di Specializzazione in Radioterapia, Università di Torino. Titolo della tesi di specializzazione: Ex vivo γ H2AX assay as a predictive biomarker of radiation sensitivity in prostate cancer patients. Relatore: Prof. Dr. U. Ricardi
14.09.2014–15.12.2015	Periodo di ricerca traslazionale, Università di Tübingen, Germania.
II Sessione 2010	Esame di Stato, Abilitazione, Università di Torino
09.2004–10.2010	Studio della Medicina e Chirurgia, Università di Torino. Titolo della tesi Tesi: The use of Four Dimensional Computed Tomography (4D-CT) in the treatment planning of stereobody radiation therapy for lung tumors: clinical results and future perspective. Relatore: Prof. Dr. U. Ricardi
09.1999–07.2004	Liceo scientifico A. Gramsci, Ivrea (Torino)

GRANTS

- “Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence”. **C. De-Colle** et al. Int J Hyperthermia, 2022
- “Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG”, Löck S, Linge A, Lohaus F, Ebert N, Gudziol V, Nowak A, Tinhofer I, Kalinauskaite G, Guberina M, Stuschke M, Balermipas P, von der Grün J, Grosu AL, Debus J, Ganswindt U, Belka C, Peecken JC, Combs SE, **De-Colle C**, Zips D, Baretton GB, Krause M, Baumann M for the DKTK-ROG. Radiotherapy and Oncology, 2022
- “Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac”. **C. De-Colle** et al. Strahlenther Onkol., 2022.
- “Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5 T MR-linear accelerator”. **C. De-Colle** et al. Clinical and Translational Radiation Oncology, 2021.
- “ γ H2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture”. A. Riedel, L. Klumpp, A. Menegakis, **C. De-Colle**, S. M. Huber, J. Schittenhelm et al. Radiotherapy and Oncology, 2021
- “Optimizing MR-Guided Radiotherapy for Breast Cancer Patients”. M. L. Groot Koerkamp, J. E. Vasmel, N. S. Russell, S. F. Shaitelman, C. N. Anandadas, A. Currey, D. Vesprini, B. M. Keller, **C. De-Colle**, K. Han et al. Front. Oncol., 2020
- “Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects”. M. Nachbar, D. Mönnich, S. Boeke, C. Gani, N. Weidner, V. Heinrich, M. lo Russo, L. Livi, J. Winter, S. Tsitsekidis, O. Dohm, D. Thorwarth, D. Zips, **C. De-Colle**. Radiotherapy and Oncology, 2020
- “Quality of life and fatigue before and after radiotherapy in breast cancer patients” F. Hauth, **C. De-Colle**, N. Weidner et al. Strahlenther Onkol., 2020
- “Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study”. **C. De-Colle**, N. Weidner, V. Heinrich et al. Strahlenther Onkol., 2019
- “ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy”. M. Guberina, A. Sak, C. Pöttgen, I. Tinhofer-Keilholz, V. Budach, P. Balermipas, J. Von der Grün, C. M. Rödel, E. Gikka, A.-L. Grosu, A. Abdollahi, J. Debus, C. Belka, S. Pigorsch, S. Combs, D. Mönnich, D. Zips, **C. De-Colle**, S. Welz, A. Linge et al. The Pharmacogenomics Journal, 2020
- “Heterotopic ossifications: role of radiotherapy as prophylactic treatment”. M.G. Ruo Redda, **C. De Colle** et al. Radiol Med., 2018
- “SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy”. **C. De-Colle**, A. Menegakis, D. Mönnich et al. Radiotherapy and Oncology, 2018
- “Ex vivo γ H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity”. **C. De-Colle**, A. Yaromina, J. Hennenlotter et al. Radiotherapy and Oncology, 2017
- “SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy”. **C. De-Colle**, D. Mönnich, S. Welz et al. Clinical and Translational Radiation Oncology, 2017

- “Insufficiency bone fracture after pelvic radiotherapy: retrospective evaluation of risk factors and dose-volume relationship analysis”. A. Ruggieri, C. Airaldi, B. Baiotto, E. Gino, L. Bianco, M. Stasi, **C. De-Colle** and M.G. Ruo Redda. European Journal of pharmaceutical and medical research, 2017
- “Hypofractionation with no boost after breast conservation in early stage breast cancer patients”. F. Arcadipane, P. Franco, **C. De-Colle** et al. Medical Oncology, 2016
- “Residual γ H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness”. A. Menegakis, **C. De-Colle**, A. Yaromina et al. Radiotherapy and Oncology, 2015
- “Once-weekly hypofractionated whole breast radiotherapy after breast conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation”. P. Rovea, A. Fozza, P. Franco, **C. De-Colle** et al. Clinical Breast Cancer, 2015

LISTA DELLE COMUNICAZIONI ORALI

- Ultra short fractionations for breast cancer and MRI Linac, invited lecture, 7st advanced AIRB course on radiobiology. Brescia, 2022
- Treatment of rectal tumors on the MR-Linac, invited lecture, 7st advanced AIRB course on radiobiology, Brescia, 2022
- Challenges of AI in MRgRT: the clinical perspective - high field experience, invited lecture, ESTRO Physics Workshop: Science in Development, Lisbon 2022
- Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence. C. De-Colle et al., Poster, 27° DEGRO Kongress. Stuttgart, 2022
- Breast cancer patient irradiation at the 1.5 T MRL – clinical protocols. C. De-Colle, invited lecture, MR-Linac Consortium Meeting. Virtuuell, 2022
- Untersuchung zur Machbarkeit der MR-geführten adaptive Strahlentherapie (MRgRT) des inoperablen nichtkleinzelligen Lungenkarzinom (NSCLC). C. De-Colle et al., Poster, DEGRO 2022
- Second cancer risk after partial breast irradiation at the 1.5 T MR-Linac. C. De-Colle et al., Vortrag, MR-Linac Consortium Meeting. Virtuuell, 2021
- Ermittlung des Zweitmalignomsrisikos nach Teilbrustbestrahlung am 1.5T MR-Linac. C. De-Colle et al., Poster, 27° DEGRO Kongress. Virtuuell, 2021
- Techniken der Strahlentherapie: heute und morgen. C. De-Colle, invited lecture, 27° DEGRO Kongress. Virtuuell, 2021
- Partial breast irradiation at the 1.5T MR-Linac: treatment time and electron stream effect analysis. C. De-Colle et al., Poster, 8th MR in RT Symposium. Heidelberg/ Virtuuell, 2020
- Partial breast irradiation at the 1.5T MR-Linac: treatment time and electron stream effect. C. De-Colle et al., Poster, ESTRO 38 Kongress. Virtuuell, 2020
- First partial breast patient treatment at 1.5T MR-Linac Unity, C. De-Colle et al., Vortrag, MR-Linac Consortium Meeting. Copenhagen, 2019

- Unity Clinical Activity Update. C. De-Colle, invited lecture, MR-Linac Consortium Meeting. Copenhagen, 2019
- Hyperthermic chest wall re-irradiation in recurrent breast cancer: a prospective observational study. C. De Colle et al. E-poster, ESTRO 37 Kongress. Milan, 2019
- Hyperthermic chest wall re-irradiation in recurrent breast cancer". C. De Colle et al. Poster, 24° DEGRO Kongress. Leipzig, 2018
- Ex vivo γ H2AX radiosensitivity assay in prostate cancer patient tumour samples. Evaluation of inter-patient and intra-patient heterogeneity". C. De-Colle et al. Poster, 26° Symposium experimentelle Strahlentherapie und klinische Strahlenbiologie. Tübingen, February 2017
- Factor 2.5 radiosensitivity difference determined by ex vivo γ H2AX assay in prostate cancer patients". C. De Colle et al. Poster, ESTRO 35 Congress. Turin, 2016
- Ex vivo γ H2AX assay in prostate cancer samples reveals substantial differences in intrinsic radiation sensitivity". C. De Colle et al. Vortrag, 25° Symposium experimentelle Strahlentherapie und klinische Strahlenbiologie. Dresden, 2016
- The volume effect in radiotherapy. C. De Colle, invited lecture, 1st advanced AIRB course on radiobiology, Brescia, 2015
- γ H2AX as a biomarker of radiation sensitivity in ex vivo irradiated samples from tumour patients" C. De Colle et al., Vortrag, 24° Symposium experimentelle Strahlentherapie und klinische Strahlenbiologie. Hamburg, 2015
- Accelerated Partial Breast Irradiation (APBI) with High Dose Rate Brachithrapy (HDR-BT): the Turin experience". C. De Colle et al., Vortrag, XXIV National AIRO Congress. Padova, 2014
- Surgical resection versus radiotherapy after CDDP/ Docetaxel induction chemotherapy in locally advanced Non Small Cell Lung Cancer (NSCLC)". C. De Colle et al., Vortrag, XXII AIRO Congress. Roma, 2012
- Impact of Four Dimensional Computed Tomography (4D-CT) in the treatment planning of Stage IA and IB NSCLC patients treated with SBRT: University of Turin experience". C. De Colle et al., Vortrag, IV AIRO Young National Congress. Roma, 2011